Jeena Sikho Lifecare Presents Q4FY26 Investor Presentation, Recommends Final Dividend
Jeena Sikho Lifecare's Q4FY26 investor presentation reveals Revenue from Operations of ₹215.55 crore and PAT of ₹45.35 crore. For FY26, Revenue was ₹801.35 crore with PAT of ₹222.18 crore. The company recommended a final dividend of ₹4.50 per share.
The investor presentation provides detailed financial performance and future outlook, which is material information for investors. The recommended dividend also has a direct financial impact on shareholders.
The company is presenting positive financial results and recommending a dividend, indicating a healthy financial performance and a commitment to returning value to shareholders.
Jeena Sikho Lifecare Limited (JSLL) has submitted an investor presentation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This presentation is being used during a meeting with investors scheduled for Tuesday, June 02, 2026, and is also available on the company's website.
The presentation highlights the company's performance for the fourth quarter and the financial year ended March 31, 2026. Key financial milestones include Revenue from Operations of ₹215.55 crore in Q4FY26, with EBITDA at ₹77.98 crore and PAT at ₹45.35 crore. For the full fiscal year FY26, Revenue from Operations reached ₹801.35 crore, with EBITDA at ₹349.63 crore and Profit After Taxes at ₹222.18 crore. The company reported strong YoY growth in Revenue from Operations of 55% for Q4FY26 and 71% for FY26, driven by increased patient volumes and expanding service reach.
In terms of patient volumes, Q4FY26 saw OPD Patient Volumes at 1.50 lakh, IPD Patient Volumes at 10,911, and Consultations (OPD & VOPD) at 67,856. The company has also expanded its operational bed capacity to 2,300 beds, with 445 beds in the pipeline.
Reflecting confidence in its performance and commitment to shareholders, the Board of Directors has recommended a final dividend of ₹4.50 per equity share for the financial year 2025-26, subject to shareholder approval at the ensuing Annual General Meeting.
What to do with a filing like this
Jeena Sikho Lifecare Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jeena Sikho Lifecare Limited. Read the original for the full detail.